ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Continuing ALK NSCLC TKI Treatment while on Chemotherapy Leads to Better Outcomes
A recent multi-center study examined outcomes for ALK-positive NSCLC patients who continued their ALK TKI while receiving platinum/pemetrexed chemotherapy after disease progression. The findings suggest that maintaining targeted therapy alongside chemotherapy may improve overall survival and reduce the risk of brain progression in certain patients.
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.
-
Understanding Guardant360 Liquid Biopsy
Guardant360 Liquid is an advanced liquid biopsy that can detect extremely small amounts of tumor DNA circulating in the bloodstream. This technology allows doctors to identify important genetic changes even when tissue biopsies are difficult to obtain.
-
Protected: Honoring a Legacy: The John Pender Scholarship Fund
There is no excerpt because this is a protected post.
-
-
True or False: Test Your Knowledge of Clinical Trials
Clinical trials are often misunderstood. This short quiz explores common myths and facts about trials, helping patients better understand participation, safety, and the role research plays in improving outcomes for ALK-positive cancers.
-
Patient Spotlight: Nikki Hirsch
After being diagnosed with Stage IV ALK-positive lung cancer in 2021, Nikki Hirsch found strength through community, advocacy, and connection. From leading the Single ALKies sessions on ALKtALK to organizing community fundraisers, Nikki shares how staying informed, supporting others, and finding joy in everyday moments help her navigate life with hope.
-
ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research
ALK Positive is proud to support Dr. Alice Shaw’s pre-clinical research advancing the understanding of ALK-positive lung cancer. Her work focuses on uncovering biological mechanisms that drive treatment resistance, with the goal of informing future therapeutic strategies and improving long-term outcomes for patients. Through this partnership, ALK Positive is investing in science that accelerates progress…
-
ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer
We’re proud to partner with Pfizer on a new grant opportunity designed to strengthen education for people diagnosed with advanced ALK-positive lung cancer. This RFP supports independent projects that help patients and care partners prepare for treatment, recognize side effects early, and access clear, inclusive resources that honor their preferences. Funding is available for organizations…
-
ALK Positive and the American Association for Cancer Research (AACR) partner to fund a two-year AACR-ALK Positive Lung Cancer Research Fellowship
ALK Positive Partners with AACR to Advance ALK-Positive Lung Cancer Research ALK Positive has partnered with the American Association for Cancer Research (AACR) to fund a two-year AACR–ALK Positive Lung Cancer Research Fellowship supporting early-career investigators in ALK-positive lung cancer research. The 2025 awardee, Alice Tzeng, MD, PhD of Dana-Farber Cancer Institute, is studying epigenetic…
-
ALK Positive Inc. Appoints Dr. Ken Culver as Executive Director & Medical Director to Lead Research and Patient Advocacy Initiatives
ALK Positive has appointed Dr. Ken Culver as Executive Director and Medical Director to guide the organization’s strategy and research investments. A physician-scientist with expertise in oncology and drug development, Dr. Culver has advanced patient-driven science and global collaborations since joining ALK Positive in 2022. His leadership marks an exciting new chapter in accelerating research…
-
Carrying Forward a Legacy: An Interview with Chad David Jasso of the Dave Jasso Foundation
The Dave Jasso Foundation exists with a dual mission: to actively fundraise for ALK Positive, supporting their critical research in the fight against ALK-positive lung cancer, and to honor the enduring legacy of Dave Jasso.